The Vienna-based medical technology startup contextflow is becoming part of the Australian group 4DMedical Limited (ASX: 4DX). As 4DMedical has just announced, a binding agreement to acquire contextflow GmbH has been signed. For the Vienna-based company specializing in AI-powered lung diagnostics, this marks an exit — for the buyer, it marks an entry into the European market.
contextflow is a Vienna-based medical imaging company founded in 2016, which emerged from the Medical University of Vienna and the European research project Khresmoi, and was supported by the Vienna University of Technology. The company develops clinical decision support software for the detection and management of lung diseases — including lung cancer, interstitial lung diseases (ILD), and COPD.
It employs proprietary AI to analyze chest CT scans, for example in the CE-certified product ADVANCE Chest CT. The technology is aimed at radiologists, healthcare providers, pharmaceutical companies, and payers. contextflow gained recognition, among other things, through its inclusion in the Philips HealthWorks Accelerator Program and through funding from the European Innovation Council. A key milestone is a reimbursement agreement for early lung cancer detection in Germany, with initial revenues expected in the third quarter of 2025.
contextflow raised an investment of €6.7 million several years ago and has also received several million euros in grants.
4DMedical is an Australian Stock Exchange-listed medical technology company focused on advanced lung imaging. On the ASX, the company most recently reached a market capitalization of approximately A$2.3 billion — equivalent to roughly US$1.5 billion. Its market value has more than twelvefold increased within a year (+1,234%), making 4DMedical one of the strongest healthcare tech stocks on the Australian stock exchange.
At the core of its technology is the patented XV Technology®, which derives functional insights into ventilation, perfusion, and lung mechanics from conventional scans. Its software portfolio includes the FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) and the CT:VQ™ solution, among others. As early as 2023, 4DMedical had expanded its AI capabilities through the acquisition of US company Imbio.
According to 4DMedical, the acquisition is being made at significantly discounted terms. The upfront payment comprises approximately A$18.56 million in cash (equivalent to approximately €11.4 million) as well as 56,235 ordinary shares. In addition, there is a performance-based earnout of up to 2.59 million zero exercise price options over two years, tied to the achievement of performance milestones. The acquired business is also expected to retain approximately A$30.8 million (€19 million) in tax loss carryforwards.
For context on the equity-based components (indicative, at a price of approximately A$4.14 per share on 1 June): the 56,235 shares currently correspond to approximately €0.14 million, and the maximum earnout to a value of up to approximately €6.6 million — with this portion being entirely dependent on the achievement of milestones and the future share price. Combined with the substantial loss carryforwards and the explicitly “discounted” terms, the sale appears more pragmatic than triumphant — despite the previously achieved reimbursement breakthrough in Germany.
“As part of the acquisition, 4DMedical retains a cumulative tax loss of €19.0 million (approx. A$30.8 million),
which may potentially be used to offset future taxable income from the Austrian business and represents a significant additional source of value,” the announcement states.
Strategically, the focus is primarily on geographic expansion. With the acquisition, 4DMedical says it immediately gains its own commercial and clinical presence in Europe, complementing its existing footholds in North America as well as Australia and New Zealand. Rather than building a new regional structure from scratch, the group is taking over an already active team, an existing customer base, and a CE-certified, MDR-compliant product portfolio already in routine clinical use.
Management estimates the market for respiratory and thoracic imaging in Europe at approximately US$1.5 to 2 billion. There is also a technological rationale: contextflow’s AI solutions for detection — such as early lung cancer screening — complement 4DMedical’s functional imaging capabilities. Together, they are intended to cover a more seamless clinical pathway from detection through diagnosis to follow-up monitoring, and to enable cross-selling within the existing customer base, particularly in markets with established reimbursement pathways such as Germany.
The move was well received by markets: 4DMedical shares rose by just over four percent on Monday, bringing the gain to approximately 14 percent over the past week.
Markus Holzer, previously CEO of contextflow, is taking on the role of General Manager of 4DMedical Europe and will be responsible for driving growth in the region. He will report to founder and CEO Andreas Fouras. This preserves the regional leadership — a central building block for 4DMedical in achieving its goal of a presence on three continents.
Aus Datenschutz-Gründen ist dieser Inhalt ausgeblendet. Die Einbettung von externen Inhalten kann in den Datenschutz-Einstellungen aktiviert werden:
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。